Global biotech group Ipsen has today announced a £22m investment and a recruitment drive for scientists in a significant expansion of its site in Wrexham.

The firm, which develops and manufactures medicines for oncology, rare diseases and speciality care, is to build a high-tech campus at its base on the town’s industrial estate.

Ipsen also announced that it has completed its latest project – construction of a world-class pilot manufacturing facility and that it has gained EU approval to make and ship products from a newly-built filling and freeze-drying facility. 

The firm has increased its headcount by 100 workers during 2017 with 80 scientists and 20 specialist manufacturing operatives taken on.

They now employ 400 workers and plan to take on more staff.

Its main product is Dysport, which is approved for use in 80 countries worldwide and in therapeutic indications including cerebral palsy, spasticity and cervical dystonia. 

The French-owned family firm has manufactured and distributed medicines from Wrexham since 1995.

The new £22m campus will increase research and manufacturing, with a new high-speed packing line and an Ipsen Academy, to train new recruits and give refreshers for existing employees. 

Secretary of State for Wales, Alun Cairns, is due to tour the global manufacturing and distribution hub this afternoon.

Mr Cairns said: “Ipsen is one of North Wales’ great success stories. Their continued expansion is a clear demonstration of the significant contribution life sciences and innovation in these specialist areas make to the region and the Welsh economy.”

Ipsen senior vice-president and head of the Wrexham site, Aidan Murphy said: “We are taking important strides in the accelerated expansion programme under way at Wrexham, which will see production grow significantly to reflect demand and company ambition.”